Select Language
PSMA
PSMA Overview
| English Name | Prostate-Specific Membrane Antigen | Approved Drugs | 6 |
| Drugs in Clinical Trials | 161 | Target Synonym | EC:3.4.17.21，GIG27，Glutamate carboxypeptidase II，NAALADase I，FOLH，Cell growth-inhibiting gene 27 protein，PSM，N-acetylated-alpha-linked acidic dipeptidase I，GCPII，Folylpoly-gamma-glutamate carboxypeptidase，Folate hydrolase 1，FOLH1，Pteroylpoly-Gamma-Glutamate Carboxypeptidase，Membrane Glutamate Carboxypeptidase，Glutamate Carboxypeptidase 2，Glutamate Carboxylase II，NAALAD1，FGCP，PSMA，MGCP，Folate Hydrolase (Prostate-Specific Membrane Antigen) 1，N-Acetylated Alpha-Linked Acidic Dipeptidase 1，Prostate Specific Membrane Antigen Variant F，Prostate-Specific Membrane Antigen，EC 3.4.17.21，NAALAdase，GCP2 |
| Highest Development Stage | Approved | ||
| English Name | Prostate-Specific Membrane Antigen |
| Target Synonym | EC:3.4.17.21，GIG27，Glutamate carboxypeptidase II，NAALADase I，FOLH，Cell growth-inhibiting gene 27 protein，PSM，N-acetylated-alpha-linked acidic dipeptidase I，GCPII，Folylpoly-gamma-glutamate carboxypeptidase，Folate hydrolase 1，FOLH1，Pteroylpoly-Gamma-Glutamate Carboxypeptidase，Membrane Glutamate Carboxypeptidase，Glutamate Carboxypeptidase 2，Glutamate Carboxylase II，NAALAD1，FGCP，PSMA，MGCP，Folate Hydrolase (Prostate-Specific Membrane Antigen) 1，N-Acetylated Alpha-Linked Acidic Dipeptidase 1，Prostate Specific Membrane Antigen Variant F，Prostate-Specific Membrane Antigen，EC 3.4.17.21，NAALAdase，GCP2 |
| Approved Drugs | 6 |
| Drugs in Clinical Trials | 161 |
| Highest Development Stage | Approved |
PSMA Product List
- Product Category
Protein (13)Beads (1)Antibody (1)Cell (1)Kits (1)
- Product Status
Launched (17)
- Species
Human (9)Cynomolgus (2)Mouse (4)Rat (1)Rabbit (1)
- Tag
His Tag (6)His Tag & Avi Tag (3)Fc Tag (2)- (4)Fc Tag & Avi Tag (2)
- Conjugate
Unconjugated (7)Biotin-labeled (5)FITC Labeled (1)- (3)PE Labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT MBP-K007 |  Human | - | Human PSMA-coupled Magnetic Beads | |||
HOT PSA-H5264 | Human | HEK293 | Human PSMA / FOLH1 Protein, Fc Tag, premium grade |  |  |  |
HOT PSA-H52H3 | Human | HEK293 | Human PSMA / FOLH1 Protein, His Tag (active enzyme, MALS verified) |  | | |
HOT PSA-H82Qb | Human | HEK293 | Biotinylated Human PSMA / FOLH1 Protein, His,Avitag™, premium grade |  | | |
HOT PSA-M5245 |  Mouse | HEK293 | Mouse PSMA / FOLH1 Protein, His Tag (active enzyme) (MALS verified) |  | | |
CEA-B242 | Human | - | Human PSMA / FOLH1 ELISA Kit | |||
CHEK-ATP185 | Human | HEK293 | HEK293/Human PSMA Stable Cell Line |  | ||
PSA-H82F7 | Human | HEK293 | Biotinylated Human PSMA / FOLH1 Protein, Fc,Avitag™ (MALS verified) |  | | |
PSA-HF244 | Human | HEK293 | FITC-Labeled Human PSMA / FOLH1 Protein, His Tag |  | | |
PSA-HP2Q3 | Human | HEK293 | PE-Labeled Human PSMA / FOLH1 Protein, His Tag (Site-specific conjugation) |  | |
Total: 17
- 1
- 2
PSMA Background
Prostate-specific membrane antigen (PSMA) is also known as Folate hydrolase 1 (FOLH1), Glutamate carboxypeptidase 2 (GCP2), N-acetylated-alpha-linked acidic dipeptidase I (NAALAD1), which belongs to the peptidase M28 family and M28B subfamily. FOLH1 / PSMA is stable at pH greater than 6.5. FOLH1 / PSMA is a type II transmembrane zinc metallopeptidase that is most highly expressed in the nervous system, prostate, kidney, and small intestine. FOLH1 / GCP-2 is homodimer and binds 2 zinc ions per subunit, and required for NAALADase activity. The catalytic activity of PSMA involved in releasing of an unsubstituted, C-terminal glutamyl residue, typically from Ac-Asp-Glu or folylpoly – gamma - glutamates. FOLH1 / GCP-2 / PSMA has both folate hydrolase and N – acetylated – alpha – linked - acidic dipeptidase (NAALADase) activity and has a preference for tri-alpha-glutamate peptides. GCP-2 / PSMA involved in prostate tumor progression and also exhibits a dipeptidyl-peptidase IV type activity. In vitro, cleaves Gly-Pro-AMC.
PSMA Synonyms
FOLH1,PSMA,GIG27,FOLH,NAALAD1,PSM,NAALADase I,GCPII,FGCP
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| 225 Actinium PSMA-617 | 225Ac-PSMA-617; 225 Actinium PSMA-617; 225Ac-PSMA 617; AAA 817 | Phase 3 Clinical | Advanced Accelerator Applications Sa, Endocyte Inc, Novartis Pharma Ag | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| Gallium-68 PSMA-617 | 68Ga-DKFZ-617; Gallium-68-PSMA-617; 68Ga-PSMA-33; 68Ga-DKFZ-PSMA -617; 68Ga-DOTA-PSMA-DKFZ -617; 68Ga-PSMA-617; PSMA-617-[68Ga]; 225 Ac-PSMA-617 | Phase 3 Clinical | Peking Union Medical College Hospital | Carcinoma, Adenoid Cystic; Prostatic Neoplasms | Details |
| Ga-68 PSMA-093 | Ga-68 P16-093; PSMA-93 Latest; PSMA-093; HBED-CC-PHENOXY-PSMA; [68Ga]P16-093 | Phase 3 Clinical | Five Eleven Pharma Inc, Indiana University, Peking Union Medical College Hospital | Glioma; Kidney Neoplasms; Prostatic Neoplasms; Sjogren's Syndrome | Details |
| Vidoflufolastat (18F) | CTT-1057-F-18; CTT-1057-18F; 18F-CTT1057; CTT-1057 | Phase 3 Clinical | Cancer Targeted Technology Llc, Washington University | Carcinoma, Renal Cell; Prostatic Neoplasms | Details |
| Lu-177-labeled PSMA ligands (Zentralklinik Bad Berka/Johns Hopkins University School of Medicine) | Phase 3 Clinical | Zentralklinik Bad Berka | Kidney Neoplasms; Prostatic Neoplasms | Details | |
| Lutetium-177 zadavotide guraxetan | Phase 3 Clinical | Curium Us Llc | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details | |
| INR-101 | INR101; INR-101; INR101 PET CT; INR101-PET/CT | Phase 3 Clinical | Cloud Nuclear Medicine (Tianjin) Co Ltd | Diagnostic agents; Prostatic Neoplasms | Details |
| 68Ga-NYM032 | 68Ga-NYM032; 68Ga-NY108; 68GaNYM032 | Phase 3 Clinical | Wuxi Nuoyu Pharmaceutical Technology Co Ltd | Contrast agents; Prostatic Neoplasms | Details |
| Nizaracianine triflutate | ZW800-1 | Phase 3 Clinical | Curadel Surgical Innovations Inc, Leiden University Medical Center | Ureteral Diseases | Details |
| ITM-24D | ITM-24D; 68Ga-PSMA-TTM | Phase 3 Clinical | ITM Isotope Technologies Munich SE | Prostatic Neoplasms | Details |
| 18F vipivotide tetraxetan | Al18F-PSMA-617; 18F-PSMA-617 | Phase 3 Clinical | Peking Union Medical College Hospital | Prostatic Neoplasms | Details |
| HRS-4357 | HRS-4357; HRS4357 | Phase 3 Clinical | Tianjin Hengrui Pharmaceutical Co Ltd | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| 64Cu-PSMA I&T | Cu-64-PSMA-I&T; 64-Copper-PSMA-I&T; Copper-64-prostate specific membrane antigen I&T; Copper Cu 64 PSMA I&T | Phase 3 Clinical | Curium Us Llc | Prostatic Neoplasms | Details |
| 64Cu-SAR-bisPSMA (Clarity Pharmaceuticals) | Phase 3 Clinical | Clarity Pharmaceuticals Ltd | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details | |
| 177Lu-DOTA-rosopatamb | 177Lu-DOTA-TLX591-CHO; TLX591 | Phase 3 Clinical | Telix Pharmaceuticals Ltd | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| [Lu177]-PNT-2002 | PNT-2002; [Lu-177]-PNT-2002; 177Lu-PNT2002; [Lu-177]-PSMA-I&T; 177Lu-PSMA-I&T | Phase 3 Clinical | Scintomics | Carcinoma, Adenoid Cystic; Carcinoma, Renal Cell; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| F-18 Florastamin | FC-303 | Phase 3 Clinical | Futurechem | Prostatic Neoplasms | Details |
| Lutetium-177-PSMA-I&T | Phase 2 Clinical | Radboud University Nijmegen | Carcinoma, Adenoid Cystic; Prostatic Neoplasms; Salivary Gland Neoplasms | Details | |
| 68Ga-PSMA-R2 (Advanced Accelerator Applications SA) | Phase 2 Clinical | Advanced Accelerator Applications Sa | Prostatic Neoplasms | Details | |
| [18F]DCFBC | [18F]DCFBC | Phase 2 Clinical | Sidney Kimmel Cancer Center, Washington University | Prostatic Neoplasms | Details |
| 177Lu-PSMA-R2 | 177Lu-PSMA-R2; 177Lu-PSMA-SR6; AAA-602 | Phase 2 Clinical | Advanced Accelerator Applications Sa | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| 89Zr-DFO-huJ591 | Zr89-J591; 89Zr-DFO-J591; 89Zr-DFO-huJ591 | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center | Prostatic Neoplasms | Details |
| Nezastomig | REGN-5678 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Renal Cell; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| 225Ac-J591 | 225Ac-DOTA-J591; 225Ac-J591; CONV 01-α; J591-Ac-225 | Phase 2 Clinical | Cornell University | Prostatic Neoplasms | Details |
| ATL-101 | J-591; Lu-177-J591; 177Lu-J591; muJ-591; huJ-591; MLN-591; MLN-591RL; ATL-101 | Phase 2 Clinical | Weill Medical College of Cornell University | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Glioma; Head and Neck Neoplasms; Kidney Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms | Details |
| [131I]MIP-1095 | 1095; [131I]MIP-1095; [131I]MIP-1466; 131I-MIP-1095; 131-I-MIP-1466; 131I-MIP-1466 | Phase 2 Clinical | Progenics Pharmaceuticals Inc | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| 225Ac-rhPSMA-10.1 | Phase 2 Clinical | Blue Earth Therapeutics Ltd | Hormone-Resistant Prostate Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details | |
| CONV-01-alpha + PSMA I&T | Phase 2 Clinical | Convergent Therapeutics Inc | Prostatic Neoplasms | Details | |
| Terbium 161- PSMA I&T | Phase 2 Clinical | Oncosia Scientific GmbH | Prostatic Neoplasms | Details | |
| [18F]PSMA-11 | F-18 PSMA-11; 18F-PSMA-11; [18F]-AlF-PSMA-11; [18F]AlF-PSMA-11 | Phase 2 Clinical | Ghent University Hospital | Prostatic Neoplasms; Thyroid Neoplasms | Details |
| PB-011 | PB011; PB-011 | Phase 2 Clinical | Primo Biotechnology Co Ltd | Neoplasms; Prostatic Neoplasms | Details |
| 68Ga-PSMA-CYC | 68Ga-PSMA-CYC | Phase 2 Clinical | First Affiliated Hospital Of Fujian Medical University | Prostatic Neoplasms | Details |
| TD-001 | TD-001 | Phase 2 Clinical | T.O.A.D. Oncology SA | Prostatic Neoplasms, Castration-Resistant | Details |
| MHB-048C | MHB048C; MHB-048C | Phase 2 Clinical | Minghui Pharmaceutical (Hangzhou) Co Ltd | Prostatic Neoplasms, Castration-Resistant; Solid tumours | Details |
| GSK-5458514 | GSK-5458514; GSK5458514 | Phase 2 Clinical | Glaxosmithkline Plc | Prostatic Neoplasms | Details |
| 161Tb-NYM032 | 161Tb-NYM032 | Phase 2 Clinical | Institute Of Nuclear Physics And Chemistry Chinese Academy Of Engineering Physics, Mianyang Central Hospital, Wuxi Nuoyu Pharmaceutical Technology Co Ltd | Prostatic Neoplasms, Castration-Resistant | Details |
| INR-102 | [177Lu]Lu-PSMA-137; INR102; INR-102 | Phase 2 Clinical | Cloud Nuclear Medicine (Tianjin) Co Ltd | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| RHN001-Dx (99mTc-PSMA) | technetium-99m (99mTc); Technetium 99m-RHN 001; 99mTc-RHN001 | Phase 2 Clinical | Heidelberg University Hospital, Telix Pharmaceuticals Ltd | Prostatic Neoplasms | Details |
| RHN001-Tx (188Re-PSMA) | rhenium-188- RHN 001; RHN001-Tx (188Re-PSMA); Rhenium-188 RHN 001 (188Re) | Phase 2 Clinical | Heidelberg University Hospital, Telix Pharmaceuticals Ltd | Prostatic Neoplasms | Details |
| AS-1986NS | AS-1986NS; AS1986NS | Phase 2 Clinical | Antelope Surgical Solutions Inc | Prostatic Neoplasms | Details |
| GenSci-143 | GenSci-143; GenSci143 | Phase 2 Clinical | Changchun GeneScience Pharmaceuticals Co Ltd | Alzheimer Disease; Prostatic Neoplasms, Castration-Resistant; Solid tumours | Details |
| 225Ac-LNC1011 | 225Ac-LNC-1011; 225Ac-LNC1011 | Phase 2 Clinical | Yantai Lannacheng Biotechnology Co Ltd | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| In-111 rosopatamab tetraxetan | Phase 2 Clinical | Convergent Therapeutics Inc | Prostatic Neoplasms, Castration-Resistant | Details | |
| Ac-225 rosopatamab tetraxetan | Phase 2 Clinical | Convergent Therapeutics Inc | Prostatic Neoplasms, Castration-Resistant | Details | |
| 68Ga-PSMA-0057 | Phase 2 Clinical | Suzhou Ruihe Pharmaceutical Technology Co Ltd | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details | |
| 177Lu-LNC1011 | 177LuLNC1011; 177Lu-LNC1011 | Phase 2 Clinical | Yantai Lannacheng Biotechnology Co Ltd | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| DGPR-1008 | DGPR1008; DGPR-1008 | Phase 2 Clinical | Xindou Biotechnology (Suzhou) Co Ltd | Contrast agents; Prostatic Neoplasms | Details |
| 177Lu-NYM032 | 177Lu-NYM032; 177LuNYM032; 177Lu-NY108 | Phase 2 Clinical | Wuxi Nuoyu Pharmaceutical Technology Co Ltd | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| 177Lu-PSMA-0057 | 177Lu-PSMA-0057 | Phase 2 Clinical | Nanjing First Hospital, Nanjing Medical University | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| [225Ac]Ac-PSMA-R2 | [225Ac]Ac-PSMA-R2; AAA802; AAA-802 | Phase 2 Clinical | Novartis Pharma Ag | Prostatic Neoplasms | Details |
| 177Lu-PSMA | 177Lu-PSMA | Phase 2 Clinical | Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori | Carcinoma, Renal Cell; Neoplasm Metastasis; Neoplasms; Prostatic Neoplasms | Details |
| [177Lu]JH020002 | [177Lu]JH020002; JH-002; JH002; 177-Lu JH-020002; Lu 177 JH020002; JH02; JH-02 | Phase 2 Clinical | Bivision Biomedical Technology (Nanjing) Co Ltd | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| 131I-PSMA-1095 | 131I-PSMA-1095 | Phase 2 Clinical | Jewish General Hospital | Prostatic Neoplasms | Details |
| 68Ga-HTK03149 | 68Ga-HTK03149 | Phase 2 Clinical | British Columbia Cancer Agency | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| 177Lu-HTK03170 | 177Lu-HTK03170 | Phase 2 Clinical | British Columbia Cancer Agency | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| ADVC-001 | 212Pb-ADVC001; 212 Pb ADVC 001; 212-lead ADVC 001; 212Pd ADVC001; [212Pb]Pb-ADVC-001; ADVC-001 | Phase 2 Clinical | Advancell Advanced In Vitro Cell Technologies Sa | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| Ga-68-NGUL | Phase 2 Clinical | Cellbion Co Ltd | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details | |
| CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, B-Cell; Lymphoma, B-Cell | Details | |
| GD2/PSMA Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR GD2/PSMA | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Solid tumours | Details |
| PSMA/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR PSMA/CD70 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
| 177Lu-rhPSMA-10.1 | 177Lu-rhPSMA-10.1; 177Lu-rhPSMA10.1; (177Lu) rhPSMA-10.1; Lutetium (177Lu) rhPSMA-10.1 (Tx IMP); Lutetium-177 rhPSMA10.1; Lutetium Lu 177 PSMA-10.1; 177Lu-rhPSMA; Lu177-rhPSMA; 177Lu Radiohybrid PSMA-10.1; 177Lu rhPSMA-10.1 | Phase 2 Clinical | Technical University Munich | Prostatic Diseases; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urogenital Neoplasms | Details |
| Lu-177-DGUL | Lu-177-DGUL; 177Lu-DOTA-GUL; PSMA-D GUL | Phase 2 Clinical | Cellbion Co Ltd | Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| 225Actinium-PSMA-I&T | FPI-2265 | Phase 2 Clinical | Excel Diagnostics And Nuclear Oncology Center | Prostatic Neoplasms, Castration-Resistant | Details |
| Olsutamig | REGN-4336 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| [177Lu]Ludotadipep | 177Lu-FC705; 177Lu-FC-705 | Phase 2 Clinical | Futurechem | Prostatic Neoplasms, Castration-Resistant | Details |
| 67Cu-SAR-bisPSMA | Phase 2 Clinical | Clarity Pharmaceuticals Ltd | Prostatic Neoplasms, Castration-Resistant | Details | |
| 99m-TC-PSMA-I&S | Phase 2 Clinical | Irccs San Raffaele | Prostatic Neoplasms | Details | |
| IS-002 | IS-002 | Phase 2 Clinical | Intuitive Surgical Medical Device Science & Technology (Shanghai) Co Ltd | Prostatic Neoplasms | Details |
| Zopocianine | OTL-78; OTL78 | Phase 2 Clinical | Endocyte Inc, Purdue University | Prostatic Neoplasms | Details |
| INO-5401 | INO-5401 | Phase 2 Clinical | Inovio Pharmaceuticals Inc | Carcinoma, Transitional Cell; Glioblastoma | Details |
| JNJ-63898081 | JNJ-63898081; JNJ-8081 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine | Neoplasms | Details |
| P28z-CAR | P28z-CAR | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center, United States Department Of Defense | Prostatic Neoplasms | Details |
| PSMA-CART cell therapy (Shanghai Bioray Laboratory) | Phase 1 Clinical | BRL Medicine Inc | Prostatic Neoplasms, Castration-Resistant | Details | |
| Autologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical Center | Phase 1 Clinical | Roger Williams Medical Center | Prostatic Neoplasms | Details | |
| CC-1 | CC-1 | Phase 1 Clinical | BiconY Therapeutics Gmbh | Prostatic Neoplasms | Details |
| Acapatamab | AMG-160 | Phase 1 Clinical | Amgen Inc | Carcinoma, Non-Small-Cell Lung; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| 177Lu-EB-vipivotide tetraxetan | [177Lu]Lu-XT033; 177-Lu-EB-PSMA-617 | Phase 1 Clinical | Beijing Xiantong International Technology Co Ltd, Peking Union Medical College Hospital | Carcinoma, Adenoid Cystic; Carcinoma, Renal Cell; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| [177Lu]-CTT-1403 | CTT-1403; [177Lu]CTT-1403; [177Lu]CTT1403; 177Lutetium CTT1403 | Phase 1 Clinical | Cancer Targeted Technology Llc | Prostatic Neoplasms | Details |
| Pelgifatamab corixetan | BAY-2315497 | Phase 1 Clinical | Bayer AG | Prostatic Neoplasms, Castration-Resistant | Details |
| anti-PSMA CAR T-cell therapy (Memorial Sloan-Kettering Cancer Center) | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Prostatic Neoplasms | Details | |
| PSMA CAR-T | Phase 1 Clinical | University Of Pennsylvania | Hormone-Resistant Prostate Neoplasms; Prostatic Neoplasms | Details | |
| PSMA/NKG2DL/FAP-targeted Hi-TCR-T cells | Phase 1 Clinical | Shenzhen Misheng Biotechnology Co Ltd | Prostatic Neoplasms; Solid tumours | Details | |
| INO-5412 | INO-5412; INO5412 | Phase 1 Clinical | Inovio Pharmaceuticals Inc | Glioblastoma | Details |
| 161Tb-LNC1011 | 161Tb-LNC1011 | Phase 1 Clinical | Yantai Lannacheng Biotechnology Co Ltd | Prostatic Neoplasms | Details |
| 225Ac-TR2205 | 225Ac-TR2205 | Phase 1 Clinical | Cancer Hospital of Shandong First Medical University | Triple Negative Breast Neoplasms | Details |
| Chimeric Antigen Receptor T Cells therapy (Orig Stone Biotech) | ACT#001 | Phase 1 Clinical | Orig Stone Biotech(Zhejiang) Co Ltd | Prostatic Neoplasms, Castration-Resistant | Details |
| BAY2616505 | BAY-2616505 | Phase 1 Clinical | Bayer AG | Prostatic Neoplasms, Castration-Resistant | Details |
| 177Lu-TWS02 | Phase 1 Clinical | Shandong University, The Affiliated Huaian No.1 People'S Hospital Of Nanjing Medical University | Prostatic Neoplasms | Details | |
| 225Ac-TWS02 | Phase 1 Clinical | Shandong University, The Affiliated Huaian No.1 People'S Hospital Of Nanjing Medical University | Prostatic Neoplasms | Details | |
| 18F-(FAl)-PSMA | Phase 1 Clinical | Pla General Hospital | Prostatic Neoplasms | Details | |
| 177Lu-PSMA-3Q | Phase 1 Clinical | The First Medical Center Of Chinese People'S Liberation Army General Hospital | Prostatic Neoplasms | Details | |
| 18F-P137 | 18F-P137 | Phase 1 Clinical | The First Affiliated Hospital Of Beijing University | Nasopharyngeal Carcinoma; Neoplasms | Details |
| 177Lu-ITG-PSMA-1 | 177Lu-ITG-PSMA-1; 177Lu-PSMA-I&T; Lu-177-ITG-PSMA-1 | Phase 1 Clinical | Lausanne University Hospital | Prostatic Neoplasms, Castration-Resistant; Sarcoma | Details |
| [64Cu]Cu-PSMA-R2 | Phase 1 Clinical | Institut De Cancerologie De L Ouest | Prostatic Neoplasms | Details | |
| Anti-PSMA CAR-NK cell therapy (Cancer Hospital Of Chinese Academy Of Medical Sciences) | Phase 1 Clinical | Cancer Hospital Of Chinese Academy Of Medical Sciences | Prostatic Neoplasms, Castration-Resistant | Details | |
| [111In]In-FL-020 | Phase 1 Clinical | Full Life Technologies Ltd | Prostatic Neoplasms, Castration-Resistant | Details | |
| PSMA-VG-01 | PSMA-VG-01 | Phase 1 Clinical | VitsGen Therapeutics Inc | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| [177Lu]Lu-PSMA-XT | [177Lu]Lu-PSMA-XT | Phase 1 Clinical | Beijing Xiantong International Technology Co Ltd | Prostatic Neoplasms, Castration-Resistant | Details |
| 64Cu-TR2205 | 64Cu-TR2205; 64CuTR2205 | Phase 1 Clinical | C-Ray Therapeutics (Chengdu) Co Ltd | Diagnostic agents; Prostatic Neoplasms | Details |
| ART-101 (Archeus Technologies) | ART-101 | Phase 1 Clinical | University of Wisconsin–Madison | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| ITM-23 | ITM-23; 161Tb- ITM23 | Phase 1 Clinical | Itm Solucin Gmbh | Prostatic Neoplasms | Details |
| [18F]F-DCFPyL | [18F]F-DCFPyL | Phase 1 Clinical | Anhui Provincial Hospital | Prostatic Neoplasms | Details |
| [18F]AlF-PSMA-N5 | [18F]AlF-PSMA-N5 | Phase 1 Clinical | Anhui Provincial Hospital | Prostatic Neoplasms | Details |
| [177Lu]Lu-BQ7876 | [177Lu]Lu-BQ7876; Lutetium-177 Labeled BQ7876 | Phase 1 Clinical | Tomsk National Research Medical Center Of The Russian Academy Of Sciences | Prostatic Neoplasms | Details |
| 68Ga-AAZTA-NI-093 | Phase 1 Clinical | First Affiliated Hospital Of Fujian Medical University | Prostatic Neoplasms | Details | |
| 61Cu-based NuriPro radiodiagnostic (NUCLIDIUM) | Phase 1 Clinical | Nuclidium AG | Prostatic Neoplasms | Details | |
| IR800-IAB2MA | IR800-IAB2MA | Phase 1 Clinical | Imaginab Inc | Kidney Neoplasms; Prostatic Neoplasms | Details |
| 177Lu-TR0471 | 177Lu-TR0471; 177LuTR0471 | Phase 1 Clinical | C-Ray Therapeutics (Chengdu) Co Ltd | Prostatic Neoplasms, Castration-Resistant | Details |
| [18F]F-PSMA-N5 | [18F]F-PSMA-N5 | Phase 1 Clinical | Anhui Provincial Hospital | Prostatic Neoplasms | Details |
| PSW-1025 | PSW-1025 | Phase 1 Clinical | Japan Agency For Medical Research And Development, Osaka University | Prostatic Neoplasms | Details |
| 68Ga-AAZTA-093 | 68Ga-AAZTA-093 | Phase 1 Clinical | First Affiliated Hospital Of Fujian Medical University | Prostatic Neoplasms | Details |
| 225Ac-ITM-22 | ITM-22 | Phase 1 Clinical | ITM Radiopharmazie Munchen GmbH | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| 99mTc-QULIC-5-P1 | 99mTc-QULIC-5-P1 | Phase 1 Clinical | First Affiliated Hospital Of Chongqing Medical University | Prostatic Neoplasms | Details |
| 68Ga-PSFA | 68Ga-PSFA | Phase 1 Clinical | First Affiliated Hospital Of Chongqing Medical University | Adenomatous Polyposis Coli | Details |
| 161Tb-SibuDAB | Phase 1 Clinical | University Hospital Basel | Prostatic Neoplasms, Castration-Resistant | Details | |
| Actinium-225 FL 020 (Full-Life Technologies) | 225-Ac FL-020; 225Ac-FL-020 | Phase 1 Clinical | Full Life Technologies Ltd | Prostatic Neoplasms, Castration-Resistant | Details |
| [Ac-225]-PSMA-62 | [Ac-225]-PSMA-62; 225Ac-PSMA-62 | Phase 1 Clinical | Point Biopharma Inc | Hormone-Sensitive Prostate Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| 111In-PSMA-Trillium | BAY3632687; BAY-3632687 | Phase 1 Clinical | Bayer AG | Prostatic Neoplasms, Castration-Resistant; Prostatism | Details |
| JNJ-9401 | JNJ-9401 | Phase 1 Clinical | Xencor Inc | Prostatic Neoplasms | Details |
| 68Ga-NTA-476 | 68Ga-NTA-476 | Phase 1 Clinical | 3B Pharmaceuticals GmbH, Genesiscares | Prostatic Neoplasms | Details |
| ABBV-969 | ABBV-969; ABBV969 | Phase 1 Clinical | Abbvie Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| BAY-3563254 | BAY-3563254; BAY3563254 | Phase 1 Clinical | Noria Therapeutics Inc, PSMA Therapeutics Inc | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatism | Details |
| JNJ-87189401 | JNJ-87189401 | Phase 1 Clinical | Janssen Research & Development Llc | Prostatic Neoplasms | Details |
| 99mTc-SY101 | [99mTc]SY101; 99mTc-SY101; 99mTcSY101 | Phase 1 Clinical | Shanghai Shiya Pharmaceutical Technology Co Ltd | Contrast agents; Prostatic Neoplasms | Details |
| Actinium-225-macropa-pelgifatamab | BAY-3546828; BAY3546828 | Phase 1 Clinical | Bayer AG | Prostatic Neoplasms, Castration-Resistant | Details |
| AMX-500 | VIR-5500; SAR-446329; SAR446329; AMX-500 | Phase 1 Clinical | Amunix Pharmaceuticals Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| [68Ga]Ga-PSMA-D5 | [68Ga]Ga-PSMA-D5 | Phase 1 Clinical | Anhui Provincial Hospital | Prostatic Neoplasms | Details |
| 177Lu-LNC1003 | 177Lu-LNC1003 | Phase 1 Clinical | Yantai Lannacheng Biotechnology Co Ltd | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| HRS-9815 | HRS-9815; HRS9815 | Phase 1 Clinical | Tianjin Hengrui Pharmaceutical Co Ltd | Diagnostic agents; Prostatic Neoplasms | Details |
| PSMA-Targeted [In-111]-Labeled Trillium Compound | Phase 1 Clinical | Ratio Therapeutics Inc | Prostatic Neoplasms | Details | |
| Autologous T cells therapy(Unicar-Therapy) | Phase 1 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Prostatic Neoplasms | Details | |
| 212Pb-NG001 | 212Pb-NG001; AB-001; AB001 | Phase 1 Clinical | ARTBIO Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| CART-PSMA cells（Nova Therapeutics） | Phase 1 Clinical | Nova Therapeutics LLC | Prostatic Neoplasms | Details | |
| 177Lu-P17-088 | 177Lu-P17-088 | Phase 1 Clinical | Peking Union Medical College Hospital | Prostatic Neoplasms, Castration-Resistant | Details |
| 177Lu-P17-087 | 177Lu-P17-087 | Phase 1 Clinical | Peking Union Medical College Hospital | Prostatic Neoplasms, Castration-Resistant | Details |
| JANX-007 | PSMA-TRACTr; JANX-007 | Phase 1 Clinical | Janux Therapeutics Inc | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| JNJ-80038114 | JNJ-80038114 | Phase 1 Clinical | Janssen Research & Development Llc | Prostatic Neoplasms | Details |
| CART-PSMA-TGFbRDN (University of Pennsylvania) | Phase 1 Clinical | University Of Pennsylvania | Prostatic Neoplasms | Details | |
| DXC-014 | DAC-014; DXC-014 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Melanoma; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours | Details |
| DXC-008 | DAC-008; DXC-008 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Prostatic Neoplasms; Sarcoma, Ewing; Solid tumours | Details |
| TNB-585 | TNB-585; AMG-340 | Phase 1 Clinical | Teneobio Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| CB-307 | CB-307; CB307 | Phase 1 Clinical | Crescendo Bioscience Inc | Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| Copper 64-DOTA-TLX 592 | 64Cu-TLX-592; 64Cu-DOTA-TLX592 | Phase 1 Clinical | Telix International Pty Ltd | Prostatic Neoplasms | Details |
| ARX-517 | JNJ-95298177; ARX-517; ARX517 | Phase 1 Clinical | Ambrx Inc | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| AVC-102 | AVC-102 | Phase 1 Clinical | AvenCell Therapeutics Inc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Kidney Neoplasms; Prostatic Neoplasms | Details |
| CBP-1018 | CBP-1018 | Phase 1 Clinical | Coherent Biopharma Suzhou Co Ltd | Carcinoma, Renal Cell; Lung Neoplasms; Prostatic Neoplasms; Solid tumours | Details |
| CCW-702 | CCW-702 | Phase 1 Clinical | Abbvie Inc, The Scripps Research Institute Inc | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| Anti-PSMA CAR T-cell therapy (TNK Therapeutics) | Phase 1 Clinical | Sorrento Therapeutics Inc | Neoplasms | Details | |
| CART-PSMA-TGFβRDN cell therapy (Tmunity Therapeutics) | TmPSMA-02 | Phase 1 Clinical | Tmunity Therapeutics Inc, University Of Minnesota, University Of Pennsylvania | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| [99mTc]TcO-ABX-474 | Clinical | Helmholtz-Zentrum Dresden-Rossendorf | Prostatic Neoplasms | Details | |
| radiolabeled AZ-093 (Five Eleven Pharma/University of Pennsylvania) | [68Ga]- AZ-093; AZ-093; AZ-093-[177Lu]; AZ-093-68Ga; Lutetium-177-AZ-093; [177Lu]-AZ-093; AZ-093-[68Ga]; AZ-093-177Lu; Gallium-68-AZ-093 | Clinical | University Of Pennsylvania | Prostatic Neoplasms | Details |
| 177Lu-PSMA-1 | Clinical | Centre Léon Bérard | Carcinoma, Renal Cell; Peritoneal Neoplasms; Prostatic Neoplasms | Details | |
| (99m)Tc-MIP-1427 | (99m)Tc-MIP-1427; 99mTc-MIP-1427 | Clinical | Molecular Insight Pharmaceuticals Inc | Prostatic Neoplasms | Details |
| 99mTc-P137 | 99mTc-P137 | Clinical | The First Affiliated Hospital Of Beijing University | Neoplasms | Details |
| 18F-TWS02 | 18F-TWS02 | Clinical | Shandong University | Prostatic Neoplasms | Details |
| [68Ga]Ga-TWS02 | 68Ga-TWS02 | Clinical | Shandong University | Prostatic Neoplasms | Details |
| 68Ga-PSMA | Clinical | The First Affiliated Hospital Of Anhui Medical University | Prostatic Neoplasms | Details | |
| [68Ga]-P137 | Clinical | Beijing Cancer Hospital | Prostatic Neoplasms | Details | |
| 177Lu-PSMA-3D1015 | Clinical | 3d Medicines Inc | Prostatic Neoplasms, Castration-Resistant | Details | |
| [At-211] PSMA-5 | [At-211] PSMA-5 | Clinical | Osaka University | Prostatic Neoplasms | Details |
| ⁶⁸Ga-labeled PSMA-targeting tracer (FindCure Biosciences ) | FindCure Biosciences (ZhongShan) Co Ltd | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Capromab pendetide | lndium-CYT-356; CYT-356; Indium-111-CYT-356; 111In CYT-356 | Approved | Eusa Pharma | ProstaScint | United States | Prostatic Neoplasms | Cytogen Corp | 1996-10-28 | Prostatic Neoplasms | Details |
| PB-01 (Primo Biotechnology) | PSMA-1007-[18F]; PB-01 (Primo Biotechnology); PB01 [18F]PSMA-1007; 18F PSMA-1007; [18F]PSMA1007; 18FPSMA-1007; [18F]PSMA-1007; 18F-PSMA-1007; [18F]PSMA 1007 | Approved | Primo Biotechnology Co Ltd | Radelumin | Carcinoma, Renal Cell; Colonic Neoplasms; Prostatic Neoplasms | Details | ||||
| Piflufolastat F 18 | Approved | Johns Hopkins University | Pylarify, Pylclari | United States | Prostatic Neoplasms | Progenics Pharmaceuticals Inc | 2021-05-26 | Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Castration-Sensitive Prostate Neoplasms; Diagnostic agents; Genital Neoplasms, Female; Metastatic breast cancer; Neoplasm Metastasis; Pancreatic Neoplasms; Prostatic Neoplasms | Details | |
| TLX-591 companion diagnostic (Telix Pharmaceuticals) | Ga-68-PSMA-11; Ga-68-PSMA; 68Ga-HBED-CC-PSMA11; AAA517; AAA-517; [68Ga]Ga-PSMA-11; TLX591-Sx; 68Ga-PSMA-IRDye; TLX591-CDx; TLX007-CDx | Approved | Advanced Nuclear Medicine Ingredients (Anmi) | Gallium Ga 68 Psma-11, Illuccix, ILLUCCIX, Locametz | United States | Prostatic Neoplasms | Telix Pharmaceuticals Ltd, University Of California, Los Angeles | 2020-12-01 | Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Diagnostic agents; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Urinary Bladder Neoplasms | Details |
| Lutetium (177Lu) vipivotide tetraxetan | PSMA-617-[177Lu]; Lutetium-177-PSMA-617; 177-Lu-PSMA-617; AAA-617; Lu-177- RLT | Approved | Radiomedix Inc | PLUVICTO, 派威妥 | United States | Prostatic Neoplasms, Castration-Resistant | Novartis Pharmaceuticals Corp | 2022-03-23 | Anemia; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Verrucous; Cytopenia; Kidney Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Thrombocytopenia | Details |
| Flotufolastat F-18 | F-18-rhPSMA-7.3; Fluorine-18 rhPSMA; rhPSMA-7.3 (18F); 18FrhPSMA-7.3; (18F)-rhPSMA-7.3; 18F-rhPSMA-7.3 | Approved | Blue Earth Diagnostics Inc, Technical University Munich | POSLUMA | United States | Prostatic Neoplasms | Blue Earth Diagnostics Ltd | 2023-05-25 | Contrast agents; Prostatic Neoplasms | Details |
Product Reviews
M***n2025-09-15
1People LikeI have several Scientists that use Acro Proteins. We used to order these on Fisher, however, I have now changed to directly through Acro as their ordering is so much easier and they fulfill order promptly and perfectly. We are starting to use more Acro products and I am excited to continue to work with this company and keep getting the same great quality of products, ease of ordering, and super quick fulfillment.- T***n2023-06-29 0People LikeI ordered this product on Monday and received it by Friday! The product came neatly packed in dry ice with secure packaging. The reagent gave me good standard curves as I titrate the concentration of PSMA for my assay. I will order again next time.
- T***n2021-09-22 2People LikeI highly recommend for this supplier company .I received this order on Sep . 03 /2021 with enough dry ice for - 80C. Thank you acrobiosystems.
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
Contact Us
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
メールアドレス
order.jp@acrobiosystems.com
アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8